What are the recommended medications for treating itching (pruritus) in adults?

Medication for Itching

For generalized pruritus without an underlying rash, start with emollients and topical doxepin (limited to 8 days, 10% body surface area, maximum 12g daily), then escalate to non-sedating oral antihistamines like fexofenadine 180mg or loratadine 10mg, and if ineffective, consider gabapentin, mirtazapine, or paroxetine 1.

Algorithmic Approach Based on Underlying Cause

The treatment of itching fundamentally depends on identifying any underlying cause, as different etiologies require completely different medications:

For Generalized Pruritus of Unknown Origin (GPUO)

Topical therapy (first-line):

• Emollients for all patients as baseline 1
• Topical doxepin - most evidence-supported topical agent, but strict limitations: maximum 8 days, 10% body surface area, 12g daily due to contact dermatitis and toxicity risks 1
• Topical clobetasone butyrate or menthol as alternatives 1
• Avoid: Crotamiton cream (Strength B - proven ineffective), calamine lotion, and topical capsaicin in GPUO 1

Systemic therapy (when topical fails):

• Non-sedating antihistamines first: Fexofenadine 180mg or loratadine 10mg, or mildly sedating cetirizine 10mg 1
• Second-line options: Paroxetine, fluvoxamine, mirtazapine, naltrexone, gabapentin, pregabalin, ondansetron, or aprepitant 1
• Consider combining H1 and H2 antagonists (e.g., fexofenadine + cimetidine) 1
• Sedating antihistamines only short-term or palliative care - long-term use may predispose to dementia 1

For Specific Underlying Conditions

Hepatic/Cholestatic Pruritus:

1. First-line: Rifampicin (Strength A - highest quality evidence) 1
2. Second-line: Cholestyramine 1
3. Third-line: Sertraline 1
4. Fourth-line: Naltrexone or nalmefene 1
5. Do NOT use gabapentin in hepatic pruritus 1

Uremic Pruritus (Kidney Disease):

• Optimize dialysis, calcium-phosphate balance, correct anemia with erythropoietin first 1
• BB-UVB phototherapy (Strength A - most effective) 1
• Medications: Capsaicin cream, topical calcipotriol, or oral gabapentin 100-300mg post-dialysis 3x/week 1
• Avoid cetirizine - proven ineffective in uremic pruritus 1
• Avoid long-term sedating antihistamines except palliative care (Strength B - dementia risk) 1

Lymphoma-Associated Pruritus:

• Cimetidine, carbamazepine, gabapentin, or mirtazapine 1
• Oral corticosteroids for incurable lymphoma 1
• Phototherapy: BB-UVB for Hodgkin's, NB-UVB for non-Hodgkin's 1

Polycythemia Vera:

• Cytoreductive therapy, aspirin, interferon-α, SSRIs, cimetidine, or atenolol 1
• Phototherapy options: NB-UVB, BB-UVB, or PUVA 1

Paraneoplastic Pruritus (Solid Cancers):

• Paroxetine, mirtazapine, granisetron, or aprepitant 1

Iron Deficiency:

• Iron replacement (Strength C) 1

Drug-Induced Pruritus:

• Opioid-induced: Naltrexone first-line (Strength B), alternatives include methylnaltrexone, ondansetron, droperidol, mirtazapine, or gabapentin 1
• Chloroquine-induced: Prednisolone 10mg, niacin 50mg, or combination; consider dapsone 1
• Trial cessation of suspected medications when risk-benefit acceptable 1

Critical Pitfalls to Avoid

1. Long-term sedating antihistamines increase dementia risk - reserve only for short-term or palliative settings (Strength B) 1

2. Cetirizine is ineffective in uremic pruritus despite being effective elsewhere 1

3. Gabapentin contraindicated in hepatic pruritus but helpful in uremic and neuropathic pruritus 1

4. Topical doxepin has strict limitations - exceeding 8 days, 10% body surface area, or 12g daily risks contact dermatitis and systemic toxicity 1

5. Antihistamines have limited efficacy in non-histamine-mediated itch (e.g., atopic dermatitis, chronic prurigo) - don't persist if ineffective after reasonable trial 2

Evidence Quality Notes

The British Association of Dermatologists 2018 guidelines 1 provide the most comprehensive, recent guideline-level evidence. Most recommendations are Strength D (lower quality evidence), with notable exceptions being:

• Rifampicin for hepatic pruritus (Strength A)
• BB-UVB for uremic pruritus (Strength A)
• Avoiding long-term sedating antihistamines (Strength B)

This reflects the overall challenge that chronic pruritus treatment remains largely empirical, with limited high-quality randomized controlled trials. The field urgently needs better evidence, but clinicians must still treat patients now using the best available data 3, 4.